

John Carstensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8261582/publications.pdf>

Version: 2024-02-01

11
papers

240
citations

1478505

6
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

335
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural Course of Clinically Localized Prostate Adenocarcinoma in Men Less Than 70 Years Old. <i>Journal of Urology</i> , 1991, 146, 96-98.	0.4	61
2	How does comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back pain and osteoarthritis. <i>BMJ Open</i> , 2012, 2, e000809.	1.9	35
3	Deferred Treatment of Clinically Localized Low Grade Prostate Cancer: The Experience From A Prospective Series at The Karolinska Hospital. <i>Journal of Urology</i> , 1994, 152, 1757-1760.	0.4	34
4	Space-time clustering of childhood lymphatic leukaemias and non-Hodgkin's lymphomas in Sweden. , 2000, 16, 1111-1116.		29
5	Adult attachment and parenting stress among parents of toddlers. <i>Journal of Reproductive and Infant Psychology</i> , 2012, 30, 289-302.	1.8	27
6	Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. <i>Acta Oncologica</i> , 2017, 56, 614-617.	1.8	25
7	Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden. <i>International Journal of Cancer</i> , 2016, 139, 543-553.	5.1	11
8	Intergenerational Cohort Study of Preterm and Small-for-Gestational-Age Birth in Twins and Singletons. <i>Twin Research and Human Genetics</i> , 2015, 18, 581-590.	0.6	7
9	RAB6C is an independent prognostic factor of estrogen receptor ⁺ positive/progesterone receptor ⁻ negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 52-60.	1.8	5
10	Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor ⁺ positive/progesterone receptor ⁻ negative breast cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 415-420.	1.0	4
11	Combined measurement of copeptin, high-sensitivity troponin T, and N-terminal proBNP improves the identification of patients at risk of cardiovascular death. <i>Cardiovascular Endocrinology</i> , 2012, 1, 68-73.	0.8	2